AstraZeneca Pharma India receives notice of termination from AstraZeneca UK

AstraZeneca Pharma India has received a notice of termination from AstraZeneca UK, conveying its decision for termination of distribution arrangements for Meronem in India. This is as a result of a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc, of its late-stage small molecule antibiotics business.

Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalized patients. The transaction reinforces AstraZeneca’s focus on developing transformational medicines in its three main therapy areas viz., Cardiovascular and Metabolic Diseases, Respiratory and Oncology, while realizing value from the strong portfolio of established and late-stage antibiotics programs through Pfizer’s dedicated development and commercialization capabilities.

The current distribution arrangements for Meronem in India will terminate in six months from August 24, 2016.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.